Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideaki Bando

Showing results (131-140 of 186) with videos related to

Pageof 19
Sort By:
Journal of Gastrointestinal Oncology|November 16, 2023
Identification of an optimal mutant allele frequency to detect activating <i>KRAS</i>, <i>NRAS</i>, and <i>BRAF</i> mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomasBennett A Caughey, Kumiko Umemoto, Michelle F Green, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2023
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 StudyGiovanni Randon, Yoshiaki Nakamura, Rona Yaeger, et al.
Frontiers in Cellular and Infection Microbiology|October 3, 2022
Fecal microbiota in patients with a stoma decreases anaerobic bacteria and alters taxonomic and functional diversitiesShunsuke A Sakai, Masato Aoshima, Kentaro Sawada, et al.
JCO Precision Oncology|August 11, 2022
Association of <i>ERBB2</i> Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2-Positive Esophagogastric and Gastric CancerKaori Hino, Tomohiro Nishina, Takeshi Kajiwara, et al.
Nature Medicine|January 16, 2023
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancerDaisuke Kotani, Eiji Oki, Yoshiaki Nakamura, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 28, 2018
Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatinTomohiro Nishina, Mizutomo Azuma, Kazuhiro Nishikawa, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2026
Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trialsKenta Iguchi, Kentaro Yamazaki, Toshihiro Misumi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 9, 2016
Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatinKazuhiro Nishikawa, Yasuhide Yamada, Kenji Ishido, et al.
BMC Cancer|December 10, 2022
IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutationTaigo Kato, Nobuaki Matsubara, Masaki Shiota, et al.
International Journal of Clinical Oncology|March 6, 2026
Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI)Taro Shibuki, Riu Yamashita, Tadayoshi Hashimoto, et al.
Pageof 19

Showing results (131-140 of 186) with videos related to

Sort By:
Pageof 19
Journal of Gastrointestinal Oncology|November 16, 2023
Identification of an optimal mutant allele frequency to detect activating <i>KRAS</i>, <i>NRAS</i>, and <i>BRAF</i> mutations in a commercial cell-free DNA next-generation sequencing assay in colorectal and pancreatic adenocarcinomasBennett A Caughey, Kumiko Umemoto, Michelle F Green, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2023
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 StudyGiovanni Randon, Yoshiaki Nakamura, Rona Yaeger, et al.
Frontiers in Cellular and Infection Microbiology|October 3, 2022
Fecal microbiota in patients with a stoma decreases anaerobic bacteria and alters taxonomic and functional diversitiesShunsuke A Sakai, Masato Aoshima, Kentaro Sawada, et al.
JCO Precision Oncology|August 11, 2022
Association of <i>ERBB2</i> Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2-Positive Esophagogastric and Gastric CancerKaori Hino, Tomohiro Nishina, Takeshi Kajiwara, et al.
Nature Medicine|January 16, 2023
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancerDaisuke Kotani, Eiji Oki, Yoshiaki Nakamura, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|June 28, 2018
Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatinTomohiro Nishina, Mizutomo Azuma, Kazuhiro Nishikawa, et al.
European Journal of Cancer (Oxford, England : 1990)|June 29, 2026
Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trialsKenta Iguchi, Kentaro Yamazaki, Toshihiro Misumi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 9, 2016
Impact of progression type on overall survival in patients with advanced gastric cancer based on randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatinKazuhiro Nishikawa, Yasuhide Yamada, Kenji Ishido, et al.
BMC Cancer|December 10, 2022
IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutationTaigo Kato, Nobuaki Matsubara, Masaki Shiota, et al.
International Journal of Clinical Oncology|March 6, 2026
Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI)Taro Shibuki, Riu Yamashita, Tadayoshi Hashimoto, et al.
Pageof 19